In vitro activity of fosfomycin against mucoid and non-mucoid Pseudomonas aeruginosa strains. (March 2020)

• Record Type: Journal Article
• Authors: Bressan, A; Rodio, DM; Stangherlin, F; Puggioni, G; Ambrosi, C; Arcari, G; Carattoli, A; Antonelli, G; Pietropaolo, V; Trancassini, M
• Is Part Of: Journal of global antimicrobial resistance. Volume 20(2020)
• Page Start: 328
• Page End: 331
• Publication Date: 2020-03
• Subjects: Fosfomycin -- Mucoid Pseudomonas aeruginosa -- Agar dilution -- Automated system; Drug resistance -- Periodicals; Drug resistance -- Periodicals; Drug resistance; Periodicals; 616.9041
• DOI: 10.1016/j.jgar.2020.02.014
• Languages: English
• ISSNs: 2213-7165

Abstract

Highlights: No difference observed in MIC distribution of fosfomycin between mucoid and non-mucoid strains. MIC50 and MIC90 were 32 μg/mL and 64 μg/mL in both mucoid and non-mucoid strains respectively. There is agreement between automated system and the reference method for the fosfomycin test. Abstract: Objectives: Pseudomonas aeruginosa is the most frequent infectious agent in cystic fibrosis patients. P. aeruginosa resistance to first line antibiotics limits therapeutic options, but the therapeutic potential of older generation antibiotics, such as fosfomycin is under investigation. Fosfomycin does not belong to any other antibiotic class and acts by inhibiting the biosynthesis of the bacterial cell wall during the initial phases. A major problem for the use of fosfomycin against P. aeruginosa is the absence of a clinical breakpoint, the last one of 32 μg/mL was proposed in 2013 by the CA-SFM (Comité de l'Antibiogramme de la Société Française de Microbiologie). Methods: Sixty-one strains of P. aeruginosa (thirty mucoid and thirty-one non mucoid) were collected from respiratory samples of cystic fibrosis patients. All isolates were identified by MALDI-TOF (Bruker, Bremen, Germany). Fosfomycin MICs against P. aeruginosa were measured using an automated system and confirmed by the gold standard method. Results: There was no significant difference between mucoid and non-mucoid strains. MIC distribution and susceptibility rates were obtained by agar dilution method and from this data we measured MIC50 and MIC90 which were equal to 32 μg/mL and 64 μg/mL, respectively. From automated method results we measured a very major error (VME), major error (ME) and categorical agreement (CA) which were equal to 0%, 11% and 89%, respectively. Comparing automated and agar dilution methods, a Cohen's kappa equal to 73% (0.726) was measured. Conclusions: Our data suggest that fosfomycin has good effect against mucoid and non-mucoid strains of P. aeruginosa and automated systems can be implemented in clinical microbiology laboratories to assess fosfomycin with rapid and reproducible results.